A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine

Research output: Contribution to journal › Review › Research › peer-review

Standard

A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. / Pellesi, Lanfranco; De Icco, Roberto; Alawie, Hassan Youssef; Andersen, Morten; Liang, David; Amirguliyev, Sarkhan; Al-Karagholi, Mohammad Al-Mahdi; Amin, Faisal Mohammad; Sessa, Maurizio.

In: Expert Opinion on Drug Safety, Vol. 20, No. 4, 2021, p. 467-474.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Pellesi, L, De Icco, R, Alawie, HY, Andersen, M, Liang, D, Amirguliyev, S, Al-Karagholi, MA-M, Amin, FM & Sessa, M 2021, 'A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine', Expert Opinion on Drug Safety, vol. 20, no. 4, pp. 467-474. https://doi.org/10.1080/14740338.2021.1866537

APA

Pellesi, L., De Icco, R., Alawie, H. Y., Andersen, M., Liang, D., Amirguliyev, S., Al-Karagholi, M. A-M., Amin, F. M., & Sessa, M. (2021). A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. Expert Opinion on Drug Safety, 20(4), 467-474. https://doi.org/10.1080/14740338.2021.1866537

Vancouver

Pellesi L, De Icco R, Alawie HY, Andersen M, Liang D, Amirguliyev S et al. A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. Expert Opinion on Drug Safety. 2021;20(4):467-474. https://doi.org/10.1080/14740338.2021.1866537

Author

Pellesi, Lanfranco ; De Icco, Roberto ; Alawie, Hassan Youssef ; Andersen, Morten ; Liang, David ; Amirguliyev, Sarkhan ; Al-Karagholi, Mohammad Al-Mahdi ; Amin, Faisal Mohammad ; Sessa, Maurizio. / A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. In: Expert Opinion on Drug Safety. 2021 ; Vol. 20, No. 4. pp. 467-474.

Bibtex

@article{6de0289ebcd245049563316023382ccc,
title = "A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine",
abstract = "Background: Erenumab has recently been approved as a pharmacological treatment for the prevention of migraine. However, the incidence estimates of adverse drug reactions (ADRs) were not consistent among studies. Consequently, pooled measures of the incidences of ADRs that accounts for inter-study heterogeneity are desirable. In addition, little is known on the factors leading to such heterogeneity. Research design and methods: Clinical trials evaluating the occurrence of ADRs related to erenumab in migraine patients were searched with Ovid MEDLINE until April 2020. Random intercept models were used to estimate the pooled incidence of the ADRs reported at least in 5 different study populations. To examine whether specific factors correlated with the pooled incidence, we performed random-effects meta-regression. Results: Of 138 retrieved references, 8 clinical trials were included in the meta-analysis. We observed a significant heterogeneity of the incidence estimates of back pain, influenza, nasopharyngitis, and upper respiratory tract infection (URTI). Most of the observed heterogeneity is ascribed to treatment duration for back pain (p = 0.045), influenza (p < 0.001) and URTI (p < 0.001), and significantly attributed to Body Mass Index (BMI) for nasopharyngitis (p < 0.001). Conclusions: Back pain, influenza, nasopharyngitis and URTI showed a significant heterogeneity of incidence estimates.",
author = "Lanfranco Pellesi and {De Icco}, Roberto and Alawie, {Hassan Youssef} and Morten Andersen and David Liang and Sarkhan Amirguliyev and Al-Karagholi, {Mohammad Al-Mahdi} and Amin, {Faisal Mohammad} and Maurizio Sessa",
year = "2021",
doi = "10.1080/14740338.2021.1866537",
language = "English",
volume = "20",
pages = "467--474",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor & Francis",
number = "4",

}

RIS

TY - JOUR

T1 - A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine

AU - Pellesi, Lanfranco

AU - De Icco, Roberto

AU - Alawie, Hassan Youssef

AU - Andersen, Morten

AU - Liang, David

AU - Amirguliyev, Sarkhan

AU - Al-Karagholi, Mohammad Al-Mahdi

AU - Amin, Faisal Mohammad

AU - Sessa, Maurizio

PY - 2021

Y1 - 2021

N2 - Background: Erenumab has recently been approved as a pharmacological treatment for the prevention of migraine. However, the incidence estimates of adverse drug reactions (ADRs) were not consistent among studies. Consequently, pooled measures of the incidences of ADRs that accounts for inter-study heterogeneity are desirable. In addition, little is known on the factors leading to such heterogeneity. Research design and methods: Clinical trials evaluating the occurrence of ADRs related to erenumab in migraine patients were searched with Ovid MEDLINE until April 2020. Random intercept models were used to estimate the pooled incidence of the ADRs reported at least in 5 different study populations. To examine whether specific factors correlated with the pooled incidence, we performed random-effects meta-regression. Results: Of 138 retrieved references, 8 clinical trials were included in the meta-analysis. We observed a significant heterogeneity of the incidence estimates of back pain, influenza, nasopharyngitis, and upper respiratory tract infection (URTI). Most of the observed heterogeneity is ascribed to treatment duration for back pain (p = 0.045), influenza (p < 0.001) and URTI (p < 0.001), and significantly attributed to Body Mass Index (BMI) for nasopharyngitis (p < 0.001). Conclusions: Back pain, influenza, nasopharyngitis and URTI showed a significant heterogeneity of incidence estimates.

AB - Background: Erenumab has recently been approved as a pharmacological treatment for the prevention of migraine. However, the incidence estimates of adverse drug reactions (ADRs) were not consistent among studies. Consequently, pooled measures of the incidences of ADRs that accounts for inter-study heterogeneity are desirable. In addition, little is known on the factors leading to such heterogeneity. Research design and methods: Clinical trials evaluating the occurrence of ADRs related to erenumab in migraine patients were searched with Ovid MEDLINE until April 2020. Random intercept models were used to estimate the pooled incidence of the ADRs reported at least in 5 different study populations. To examine whether specific factors correlated with the pooled incidence, we performed random-effects meta-regression. Results: Of 138 retrieved references, 8 clinical trials were included in the meta-analysis. We observed a significant heterogeneity of the incidence estimates of back pain, influenza, nasopharyngitis, and upper respiratory tract infection (URTI). Most of the observed heterogeneity is ascribed to treatment duration for back pain (p = 0.045), influenza (p < 0.001) and URTI (p < 0.001), and significantly attributed to Body Mass Index (BMI) for nasopharyngitis (p < 0.001). Conclusions: Back pain, influenza, nasopharyngitis and URTI showed a significant heterogeneity of incidence estimates.

U2 - 10.1080/14740338.2021.1866537

DO - 10.1080/14740338.2021.1866537

M3 - Review

C2 - 33337920

VL - 20

SP - 467

EP - 474

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 4

ER -

ID: 253349428